表紙
年間契約型資訊服務

美國的青光眼市場:季報

US Glaucoma Market Quarterly Updates

出版商 Market Scope, LLC 商品編碼 644710
出版日期 4 Issues/Year 內容資訊 英文
價格
美國的青光眼市場:季報 US Glaucoma Market Quarterly Updates
出版日期: 4 Issues/Year 內容資訊: 英文
簡介

本報告提供美國的青光眼治療市場上主要標準相關分析,青光眼治療的投藥計劃,患者的藥物使用,藥物遵守,管分流術,引流設備,手術數量和定位,雷射小梁網整型術,及臨床實驗中治療藥的投資等相關彙整。

目錄

  • 執行概要
  • 患者的一次診斷
  • 青光眼患者的治療
  • 被診斷青光眼
  • 藥物治療中的患者
  • 傳統的過濾手術
  • 管分流術
  • express (使用了植入的過濾手術)
  • 雷射手術
  • 其他青光眼手術
  • 除去青光眼的外科手術 (雷射手術)
  • 藥物治療中的患者數
  • 青光眼的投藥使用:各患者數
  • 青光眼的投藥使用:一線治療
  • 投藥遵守
  • 青光眼患者的白內障情形
  • 青光眼管分流術
  • 其他青光眼手術
  • 由於雷射小梁網整型術的青光眼手術
  • 雷射為基礎的青光眼手術數量
  • 青光眼手術的定位
  • 診療的類型
  • 臨床實驗中的青光眼治療藥的投資
  • 青光眼手術的有效性
  • 全年預測、前一年的比較
目錄

We collect data on a quarterly basis from US glaucoma specialists on a range of practice of medicine and practice management issues. The data we collect are analyzed and presented in our US Glaucoma Quarterly Updates.

New in 2019 - comprehensive analysis of MIGS stent devices, canal-based procedures, and newly approved glaucoma medications.

KEY METRICS:

  • Glaucoma treatment regimen;
  • MIGS usage;
  • Patient medication usage;
  • Medication compliance;
  • Glaucoma tube shunts;
  • Glaucoma drainage devices;
  • Other glaucoma devices and treatments;
  • Laser trabeculoplasty;
  • Interest level in investigational glaucoma treatments.

Market Scope has been surveying United States ophthalmologists quarterly for over 20 years. The resulting data are analyzed and presented in our Quarterly Update Reports.

This update is designed to improve your decision-making process with an assessment of current market conditions and the identification of significant market trends. Each update includes full-year forecasts, comparisons with prior years, and trend analysis.

OUR PROCESS:

Every quarter, Market Scope surveys 3,500+ doctors from all specialties in order to produce these updates. We survey on procedure volumes, pricing and fees, product preferences, treatment plans, adoption of new technologies, and much more.

Beyond survey data, Market Scope sources additional information from our proprietary disease models, database of refractive and cataract specialists, primary research, and public data sources. In some cases, this additional information is used to extrapolate survey data to total market estimates.